TY - JOUR
T1 - Vaccinology in the third millennium
T2 - Scientific and social challenges
AU - Poland, Gregory A.
AU - Whitaker, Jennifer A.
AU - Poland, Caroline M.
AU - Ovsyannikova, Inna G.
AU - Kennedy, Richard B.
N1 - Funding Information:
Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., CSL Biotherapies, Avianax, Dynavax, Novartis Vaccines and Therapeutics, Emergent Biosolutions, Adjuvance, and Microdermis. Drs. Poland and Ovsyannikova hold two patents related to vaccinia and measles peptide research. JA Whitaker receives funding for Mayo Clinic research from Pfizer Independent Grants for Learning and Change. RB Kennedy is funded by Merck Research Laboratories to study waning immunity to mumps. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Funding Information:
The authors were supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers U01AI089859 , N01AI40065 , R37AI048793 , and R01AI033144 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
PY - 2016/4
Y1 - 2016/4
N2 - The epidemiology of deaths due to vaccine-preventable diseases has been significantly and positively altered through the use of vaccines. Despite this, significant challenges remain in vaccine development and use in the third millennium. Both new (Ebola, Chikungunya, Zika, and West Nile) and re-emerging diseases (measles, mumps, and influenza) require the development of new or next-generation vaccines. The global aging of the population, and accumulating numbers of immunocompromised persons, will require new vaccine and adjuvant development to protect large segments of the population. After vaccine development, significant challenges remain globally in the cost and efficient use and acceptance of vaccines by the public. This article raises issues in these two areas and suggests a way forward that will benefit current and future generations.
AB - The epidemiology of deaths due to vaccine-preventable diseases has been significantly and positively altered through the use of vaccines. Despite this, significant challenges remain in vaccine development and use in the third millennium. Both new (Ebola, Chikungunya, Zika, and West Nile) and re-emerging diseases (measles, mumps, and influenza) require the development of new or next-generation vaccines. The global aging of the population, and accumulating numbers of immunocompromised persons, will require new vaccine and adjuvant development to protect large segments of the population. After vaccine development, significant challenges remain globally in the cost and efficient use and acceptance of vaccines by the public. This article raises issues in these two areas and suggests a way forward that will benefit current and future generations.
UR - http://www.scopus.com/inward/record.url?scp=84962197773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962197773&partnerID=8YFLogxK
U2 - 10.1016/j.coviro.2016.03.003
DO - 10.1016/j.coviro.2016.03.003
M3 - Review article
C2 - 27039875
AN - SCOPUS:84962197773
VL - 17
SP - 116
EP - 125
JO - Current Opinion in Virology
JF - Current Opinion in Virology
SN - 1879-6257
ER -